Granted Patent
B2
US 12,403,152 · App. 17/254,417 · Granted Sep 2, 2025
Compositions and methods using a nicotinamide adenine dinucleotide (NAD
Assignee:
Societe des Produits Nestle S.A.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione, in particular neurodegenerative disease, depression, anxiety, decreased/low motivation, impaired cognitive function, mild cognitive impairment. The composition contains an effective amount of a combination of a Nicotinamide Adenine Dinucleotide (NAD + ) precursor and at least one ketone or ketone precursor. The composition can be an enterally administered composition such as an orally administered food product or food supplement.
Claims (4)
1. A method of (1) reducing risk, incidence and/or severity of or (2) mitigating deterioration of brain structure and function associated with the onset of Alzheimer's Disease (AD) in an individual in need thereof, the method comprising administering to the individual an effective amount of a composition consisting essentially of Tryptophan and medium chain triglycerides (MCTs).
2. The method according to claim 1 , wherein the composition is administered enterally.
3. The method according to claim 1 , wherein the composition is selected from the group consisting of a food product, a food supplement, an oral nutritional supplements (ONS), a medical food, and combinations thereof.
4. The method according to claim 1 , wherein at least a portion of the Tryptophan is administered in the same composition as at least a portion of the MCTs.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 6, 2025
From: CUENOUD, BERNARD; SEVERIN, INDIA; STEINER, PASCAL
To: NESTEC S.A.
Reel/Frame 071945/0289 →
MERGER
Recorded Aug 6, 2025
From: NESTEC S.A.
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 072350/0892 →
Continuity (2)
Provisional Application
62688045
· Jun 21, 2018
References Cited (52)
US 9283263B2
· Westerlund et al.
· 2016
[cited by applicant]
US 20030158237A1
· Saragovi et al.
· 2003
[cited by applicant]
US 20090104171A1
· Pardee et al.
· 2009
[cited by applicant]
US 20090253781A1
· Veech
· 2009
[cited by applicant]
US 20160250169A1
· Perez
· 2016
[cited by examiner]
AU 2014298629A1
· 2016
[cited by applicant]
CN 105050594A
· 2015
[cited by applicant]
CN 107847475A
· 2018
[cited by applicant]
CN 107847513A
· 2018
[cited by applicant]
EP 0276559
· 1988
[cited by applicant]
EP 0726073
· 1996
[cited by applicant]
WO 0185178A1
· 2001
[cited by applicant]
WO 2007001883
· 2007
[cited by applicant]
WO 2007115282
· 2007
[cited by applicant]
WO 2008011363
· 2008
[cited by applicant]
WO 2009002145
· 2008
[cited by applicant]
WO 2010021766A1
· 2010
[cited by applicant]
WO 2011082111
· 2011
[cited by applicant]
WO 2012071459A1
· 2012
[cited by applicant]
WO 2015018913A1
· 2015
[cited by applicant]
WO 2016149277
· 2016
[cited by applicant]
WO 2017042198A2
· 2017
[cited by applicant]
WO 2017062311
· 2017
[cited by applicant]
WO 2017109195
· 2017
[cited by applicant]
WO 2017158132A1
· 2017
[cited by applicant]
Oxford English Dictionary, Definition of “to prevent”, accessed Dec. 7, 2023.
[cited by examiner]
Minnesota Evidence-based Practice Center, “Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia” Mar. 2017, Agency for Healthcare Research and Quality…
[cited by examiner]
Mayo Clinic “Mild Cognitive Impairment (MCI)—Symptoms and Causes”, website updated Aug. 17, 2017, accessed via Wayback Machine on Dec. 7, 2023. https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/sy…
[cited by examiner]
Mayo Clinic “Dementia—Symptoms and Causes”, website updated Aug. 2, 2017, accessed via Wayback Machine on Dec. 7, 2023. https://www.mayoclinic.org/diseases-conditions/dementia/symptoms-causes/syc-20352013 (Year: 2017).
[cited by examiner]
Lopez, O. L. “Mild Cognitive Impairment” 2013, Continuum, vol. 19, pp. 411-424. (Year: 2013).
[cited by examiner]
Cunnane, S. C.; et al. “Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease” 2016, Annals of the New York Academy of Sciences, vol. …
[cited by examiner]
Elamin, E.; et al. “Ketone-Based Metabolic Therapy: Is Increased NAD+ a Primary Mechanism?” 2017, Frontiers in Molecular Neuroscience 2017, vol. 10, article 377. (Year: 2017).
[cited by examiner]
Douris, N.; et al. “Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet” 2015, Biochimica et Biophysica Acta, vol. 1852, pp. 2056-2065. (Year: 2015).
[cited by examiner]
Powanda, M. C.; et al. “Bvidence for a Linear Correlation between the Level of Dietary Tryptophan and Hepatic NAD Concentration and for a Systematic Variation in Tissue NAD Concentration in the Mouse and the Rat” 1970, …
[cited by examiner]
Pinto, A.; et al. “Anti-Oxidant and Anti-Inflammatory Activity of Ketogenic Diet: New Perspectives for Neuroprotection in Alzheimer's Disease” 2018, Antioxidants, vol. 7, 63 (published Apr. 28, 2018). (Year: 2018).
[cited by examiner]
Porter, R. J.; et al. “Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly” 2003, Psychological Medicine, vol. 33, pp. 41-49. (Year: 2003).
[cited by examiner]
Yang, Y.; Sauve, A. A. “NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy” 2016, Biochimica et Bophysica Acta, vol. 1864, pp. 1787-1800. (Year: 2016).
[cited by examiner]
Liu, C.-C.; et al. “Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy” 2013, Nature Reviews Neurology, vol. 9, pp. 106-118. (Year: 2013).
[cited by examiner]
Liu et al. “Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession” Neurobiology of Aging, 2013, vol. 34, pp. 1564-1580.
[cited by applicant]
Ogrodnik et al., “Cellular Senescence Drives Age-Dependent Hepatic Steatosis”, Nature Communications, vol. 08, Issue No. 01, Jun. 13, 2017, pp. 1-12, XP055648710.
[cited by applicant]
“Pyrone”, Wikipedia, Retrieved from <URL: https://en.wikipedia.org/wiki/Pyrone>, 2024, 1 Page.
[cited by applicant]
Office Action Received for Application No. BR112020022985.7, mailed on Apr. 10, 2023, 5 Pages(1 Page of English Translation and 4 Pages of Official Copy).
[cited by applicant]
Office Action Received for Application No. CN201080038137.7, mailed on Mar. 17, 2023, 15 Pages(7 Pages of English Translation and 8 Pages of Official Copy).
[cited by applicant]
“Blue Raspberry Flavoured Pre-Exertion Performance Optimizer”, Mintel, Record Id 5515873, Apr. 2018, 3 Pages.
[cited by applicant]
Office Action Received for Application No. CN201980038137.7, mailed on Mar. 17, 2023, 15 Pages(7 Pages of English Translation and 8 Pages of Official Copy).
[cited by applicant]
Australian Office Action for Appl No. 2019290926 dated Aug. 26, 2024, 5 pages.
[cited by applicant]
Aragon et al., “Age-related Muscle Anabolic Resistance: Inevitable or Preventable?”, Nutrition Reviews, vol. 81, Issue No. 4, 2023, pp. 441-454.
[cited by applicant]
Spaulding et al., “Nutraceutical and Pharmaceutical Cocktails Did Not Improve Muscle Function or Reduce Histological Damage in D2-mdx Mice”, Journal of Applied Physiology, vol. 127, Issue No. 4, Oct. 14, 2019, pp. 1058-…
[cited by applicant]
European Office Action for Appl No. 19 728 593.5-1109 dated Jun. 16, 205, 12 pages.
[cited by applicant]